TherapeuticsMD, Inc. (TXMD) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TXMD Revenue Growth
Revenue Breakdown (FY 2023)
TXMD's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
By Geography
TXMD Revenue Analysis (2013–2024)
As of May 8, 2026, TherapeuticsMD, Inc. (TXMD) generated trailing twelve-month (TTM) revenue of $2.8 million, reflecting explosive growth of +43.3% year-over-year. The most recent quarter (Q3 2025) recorded $784,000 in revenue, down 17.6% sequentially.
Looking at the longer-term picture, TXMD's 5-year compound annual growth rate (CAGR) stands at -48.7%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $70.0 million in 2022.
Revenue diversification analysis shows TXMD's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PGNY (+6.6% YoY), DARE (-103.0% YoY), and ANIP (+43.8% YoY), TXMD has underperformed the peer group in terms of revenue growth. Compare TXMD vs PGNY →
TXMD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TXMDCurrent | $3M | +43.3% | -48.7% | -270.3% | |
 PGNY | $1.3B | +6.6% | +30.2% | 6.6% | |
 DARE | $9,784 | -103.0% | - | -239692.2% | |
 ANIP | $883M | +43.8% | +33.5% | 12.6% | |
 EVAX | $8M | +125.8% | - | -122.7% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% |
TXMD Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.8M | +35.3% | $1.8M | 100.0% | $-4,760,000 | -270.3% |
| 2023 | $1.3M | -98.1% | $1.3M | 100.0% | $-8,523,000 | -654.6% |
| 2022 | $70.0M | +2619.1% | $68.6M | 98.0% | $1.2M | 1.7% |
| 2021 | $2.6M | -96.0% | $1.2M | 45.5% | $-79,577,000 | -3092.8% |
| 2020 | $64.9M | +30.7% | $48.9M | 75.4% | $-155,541,000 | -239.8% |
| 2019 | $49.6M | +208.4% | $43.3M | 87.2% | $-151,205,000 | -304.6% |
| 2018 | $16.1M | -4.0% | $13.4M | 83.0% | $-130,220,170 | -808.8% |
| 2017 | $16.8M | -13.3% | $14.1M | 84.3% | $-77,628,710 | -462.7% |
| 2016 | $19.4M | -3.9% | $15.2M | 78.4% | $-90,253,600 | -466.3% |
| 2015 | $20.1M | +34.1% | $15.6M | 77.6% | $-85,190,185 | -422.9% |
See TXMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TXMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TXMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTXMD — Frequently Asked Questions
Quick answers to the most common questions about buying TXMD stock.
Is TXMD's revenue growth accelerating or slowing?
TXMD revenue is accelerating at +43.3% year-over-year, exceeding the 5-year CAGR of -48.7%. TTM revenue reached $3M. Growth momentum has increased versus prior periods.
What is TXMD's long-term revenue growth rate?
TherapeuticsMD, Inc.'s 5-year revenue CAGR of -48.7% reflects the sustained expansion pattern. Current YoY growth of +43.3% is above this long-term average.
How is TXMD's revenue distributed by segment?
TXMD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.